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FIRST EXPERIENCES WITH A NEW ANTI-HYPERTENSIVE AGENT
'DARENTHIN'
Roy MORRIS, M.D., M.R.C.P.E., Johannesburg
That the long-term management of severe hypertension is
far from satisfactory will be abundantly clear to most practi-
tioners. The indications for 'treatment, as well as the lack
of unanimity which exists, are put forth succintly in a recent
D1aSterly review of the subject by Turner.1,z
With the advent of the ganglion-blocking agents it ap-
peared that 'medical sympathectomy' had become possible.
Experience soon showed, however, that in the majority of
cases the treatment was worse than the disease, and patients
preferred to suffer the relatively minor symptoms of their
disorder rather than the persistent agony of the toxic effects
of drugs (dry mouth, severe constipation, visual disturbances,
difficulty in urinating, impotence, lassitude, etc.).
In the United States of America there was a swing away
from ganglion blockade towards older drugs such as hydral-
lazine and veratrum, and surgical sympathectomy remained
in favour.
A new impetus has been given to therapy with the advent
of chlorothiazide· and its derivatives, combined with pre-
viously used drugs. This served not only to increase the
anti-hypertensive effects, but also to increase the cost of
treatment and to add new side-effects.
Shortly after the publication of a promising report by
Boura et al., 3 the manufacturers of Darenthin were kind
enough to let me have a trial supply.
Da:renthin (bretylium tosylate), briefly, is a drug which
accumulates selectively in the sympathetic ganglia, post-
ganglionic sympathetic fibres and, in general, in those
organs with a rich adrenergic innervation, thereby decreasing
vascular tone. This effect may be reversed by the administra-
tion of adrenergic substances. It appears that only the nor-
adrenaline produced locally at nerve endings is inhibited.
THE TRIAL
So far 7 patients have received the drug for periods varying
from 21 to 70 days. The conditions of the trial were un-
controlled, and are just those which obtain in everyday
practice. No patient was given bed rest, and everyone
went about his usual occupation. Blood pressures in all
instances had been recorded many times before treatment
began, and were checked daily after its commencement,
usually about 2 hours after a dose of the drug had been
taken. Pressures were recorded after the patient had been
standing for at least 2 minutes. Due to the mode of action
of Darenthin, there is no point in recording a recumbent
blood pressure as it will necessarily be in the pre-treatment
region.
Case 1
Miss W., aged 14, has chronic glomerulonephritis with albu-
minuria, fundal exudates, left ventricular hypertrophy and a
blood pressure of 200/130 mm. Hg (fixed). The blood urea was
28 mg. %, maximum urinary concentration 1,020 and the excre-
tion on intravenous pyelography was good. She was given reser-
pine and ganglion blockade with a drop in the standing blood
presswe to 155/100 mm. Hg, but she complained of visual diffi-
culty and nausea. On 5 October 1959, Darenthin was commenced,
\lSing 600 mg. daily. A week later the blood pressure was 130/85,
gnd again a week later 150/105 mm. Hg. The dose was increased
to 1 g. daily without affecting the blood pressure significantly,
Imt no side-effects were noted.
Case 2
Mr. J., aged 46, suffers from malignant hypertension as evidenced
by gross albuminuria, marked left ventricular hypertrophy with
a strain pattern on the ECG, visual symptoms and a small patch
of exudate in one fundus.
The pre-treatment blood pressure was about 240/150 mm. Hg
and a good response could be obtained with reserpine, a ganglion
blocker, and chlorothiazide. He felt, however, that life under
these conditions was not worth living and ultimately stopped
treatment of his own accord and consulted a naturopath. He
returned to me feeling very well indeed, but his blood pressure
was 240/160 mm. Hg. Darenthin was administered, starting on
600 mg. daily. He complained of some looseness of the bowels
and transient stuffiness of the nose as well as tiredness. Daily
blood pressure recordings were as follows: 190/140, 160/130,
140/110 mm. Hg. The dose was increased to a maximum of 2 g.
daily, at which stage he fainted one morning. A reduction to
1,600 mg. daily has given reasonable control between 120/90
and 130/95 mm. Hg. This patient complained so much of lethargy
that the drug was stopped for 3 days, after which he said he felt
well, but the blood pressure had risen to 190/150 mm. Hg. Treat-
ment is being recommenced.
Case 3
Mrs. S., aged 55, hypertensive for' 6 years at least, had received
all the usual forms of therapy with unpleasant side-effects and
discontinued all treatment a week before the consultation. Her
blood pressure at rest was 200/130 mm. Hg; an auricular gallop
was present, and arteriovenous nicking in the optic fundi, as
well as spasm and irregularity of the vessels. ECG within normal
limits, urine free of albumin and sugar. Noteworthy was the
fact that two sisters died of the sequelae of hypertension, and
one sister, alive, has hypertensive heart disease.
On 600 mg. of Darenthin daily the blood pressure fell to 115/80,
and then rose to 200/130 and 180/120 mm. Hg. The dosage
was increased to 1,200 mg. and subsequent pressures have been
130/80, 145/95 and 125/85 mm. Hg. There have been no side-
effects.
Case 4
The pre-treatment blood-pressure levels of Mr. B., aged 50,
averaged 235/150 mm. Hg. Treatment with other drugs had
brought it down to about 185/115 mm. Hg, with slight side-
effects from the drugs. He was given Darenthin 100 mg. t.d.s.,
and on the second day he fainted. About an hour later the systo1ic
blood pressure was 70 mm. Hg. After this he appeared to become
resistant to the drug, so his doctor built up the dosage to a total
of 1,800 mg. daily. At this stage the patient complained of dizzi-
ness and said he did not feel well. The reason for this becomes
apparent from the following blood pressure readings: Erect,
after 3 minutes the blood pressure was 155/110, at 5 minutes
130/100, and at 7 minutes 110/90 mm. Hg. At that time dizziness
appeared and no doubt further immobile standing would have
produced an even greater fall.
This illustrates one of the difficulties in adjusting the dose,
for this patient was being overdosed and casual blood pressure
recordings indicated just the opposite.
Case 5
Mrs. C., aged 50. Long-standing malignant hypertension in
the region of 250/130 mm. Hg. She responded to ganglion blockers
with a pressure of 180/80 mm. Hg, with marked toxic effects.
After 10 days on Darenthin, 800 mg. daily, her blood pressure
was 200/90 mm. Hg and there were no side-effects. After about
10 days she appeared to become resistant to the drug and the
blood pressure rose to 220/130 mm. Hg. The dosage was not
increased, and then, as signs of congestive failure appeared, the
drug was stopped. The patient had been in failure previously.
This case does not represent a fair trial of the drug.
Case 6
Mrs. M., aged 47, had been hypertensive for many years, the
blood pressure being in the region of 250/120 mm. Hg. She
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had always had tachycardia. She had taken reserpine for 4 years
without much effect, and could not tolerate ganglion-blocking
agents. This patient's blood pressure, owing to a misunderstanding,
had always been measured in the sitting position, averaging
180/100 mm. Hg on 600 mg. of Darenthin daily. Very likely
a standing blood pressure would have given lower figuresrepre-
senting adequate control. It is of interest that her tachycardia
has disappeared and she reports feeling better than before.
Case 7
A medical practitioner, aged about 45, had been severely hyper-
tensive for many years with an untreated blood-pressure level
of 260/160 mm. Hg. His blood urea was 51 mg. %. He had been
treating himself with hydrallazine, reserpine, and ganglion-blocking
agents, but suffered severe and distressing side-effects.
He commenced taking Darenthin, 600 mg. daily, and the blood
pressure came down to 180/110 mm. Hg. The dosage was then
gradually increased to a total of 1,600 mg. daily withoUl much
improvement. It was therefore lowered again to 600 mg. daily,
and dichlorothiazide, one tablet, was taken every alternate day.
It has been noted that after taking the dichlorothiazide the blood
pressure falls to about 100/70 mm. Hg and then gradually rises
over the next 48 hours. This patient is delighted with the results
and absence of toxic effects of his new treatment.
DISCUSSION
Darenthin is an effective antihypertensive agent and appears
to be free of toxicity. One patient complained of a blocked
nose, but this passed off and may not have been due to the
drug. A few have noted some tiredness and say they sleep
abnormally well. Two patients have had postural faints.
In one case the systolic blood pressure an hour later was 70,
and in the other case 80 mm. Hg.
The drug acts fully only when patients are in the erect
position, partially when sitting, and hardly at all when
recumbent. It remains to be seen whether sufficient pro-
tection can be given to a hypertensive patient during his
standing hours to safeguard him from the effects of the
disorder, or whether it will be advisable to use, in com-
bination, some drug which affects the blood pressure in
recumbency (probably a drug with a central site of action).
There is no doubt that the advent of bretylium tosylate
marks a major advance in the treatment of hypertension,
and is the forerunner of further progress.
CO CLUSIO S
1. Seven hypertensive patients have been treated with
bretylium tosylate (Darenthin).
2. At one time or another the drug lowered the blood
pressure significantly in all cases, even to the point of fainting.
3. Some patients seem to develop a 'resistance' to the
drug, but it is felt that this is more apparent than real and
is probably due to a faulty technique in recording the blood
pressure.
4. Darenthin, in the doses used, is quite free of serious
side-effects.
5. Care must be taken, when adjusting the dosage, that
the minimum blood pressure reading is obtained, and for
this the patient should be allowed to stand for several minutes.
6. It is possible that the addition of small doses of cWoro-




This patient's blood pressure has remained in the region of
150/100 mm. Hg. No side-effects have occurred and the heavy
exudates in the fundi have all but cleared.
Case 2
Much of this patient's symptomatology can be attributed to
renal dysfunction, for a recent blood-urea estimation gave a figure
of 11 0 mg. %, with a serum potassium of 3· I m.Eq.jJ. After
recommencement of treatment, control of the blood pressure has
remained very satisfactory, in the region of 130/90 mm./Hg.
Case 3
This patient seems to have developed resistance to the drug.
On 1,600 mg. daily, supplemented with a daily dose of 50 mg.
of Esidrex, her standing blood pressure remains in the region of
170/110 mm. Hg. Reserpine has been added, and the administra-
tion of Esidrex stopped. She insists, however, that she has never
felt better and has developed the ability to sleep soundly. This
has been mentioned by other patients too.
Case 7
A repeat blood urea on the patient showed a drop from 51
to 43 mg. % since the institution of Darenthin therapy.
Case 8
Since originally writing this paper, one further patient has
been on treatment for over I month. She is a lady aged 50,
who has had marked uncomplicated hypertension for many
years, culminating in severe headaches and incapacitating vertigo.
Treatment with reserpin"e, cWorothiazide and a ganglion-blocking
agent was given, but the patient felt miserable and was unwilling
to cooperate. Her treatment was then changed to Darenthin
without supplementary medication and her blood pressure has
remained between 130/80 and 150/100 mm. Hg. The pre-treatment
level was about 240/150 mm. Hg.
On 1,200 mg. of Darenthin daily her blood pressure fell to
80 systolic and she complained of weakness and dizziness. The
dose was therefore reduced to 800 mg. with a resulting slight
rise in pressure and abolition of symptoms.
I should like to thank Mr. B. Cuppelditch, of Burroughs Well-
come & Co. (South Africa) Ltd., for generous supplies of Daren-
thin, and my colleagues for information on patients under their
care.
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